Skip to content
Sunday 6 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,831.09
0.00%
DAX
26,046.40
+0.17%
CAC 40
8,278.77
-0.09%
STOXX 50
6,392.93
+0.16%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 12 February 2024 5:30 am  |  Updated:  Thursday 08 February 2024 7:03 pm

Britain’s ‘science superpower’ ambition will mean nothing if we don’t upgrade our labs

By: Orestis Tzortzoglou

Add as a preferred source on Google
The Pfizer/BioNTech Covid jab will be sold in UK high street pharmacies from next month.
The Pfizer/BioNTech Covid jab will be sold in UK high street pharmacies from next month.

The UK’s scientists are world-leading, but their research will be held back if we don’t upgrade our lab spaces and infrastructure, writes Orestis Tzortzoglou

Chancellor Jeremy Hunt’s Autumn Statement, delivered in November, confirms that the government is doubling down on its ambitions to transform Britain into a US-style supercluster akin to Silicon Valley. But for this to be achieved, the delivery of physical infrastructure that powers this drive will be vital.

Stepping up to the despatch box, Jeremy Hunt promised to bring forward his Mansion House reforms and invest £4.5bn over five years to attract investment in strategic sectors, like advanced manufacturing, technology and life sciences. 

In a bid to replicate the success of US life sciences, the UK government is aiming to harness the financial power of pension funds to help start-ups and scale-ups commercialize research and discovery. Announced in July, the chancellor’s Mansion House Compact is an agreement by pension providers to allocate a minimum five per cent to unlisted equities through defined contribution (DC) pension funds, and other sources of long-term savings, by 2030.  

To ensure the success of the government’s investment it must also extend its support beyond financial investment to research and development and recognise that there should also be a commitment to bolster strategic infrastructure in key supporting markets. Physical infrastructure comes in the form of both assets and buildings; investing in grid reinforcement to provide ample power, addressing water shortages and advancing sustainable transport initiatives will enable the UK to become a science superpower.

Strategic government policies aimed at fostering economic growth are successfully building an environment where innovators feel empowered to create and investors are encouraged to invest, effectively serving as a catalyst for progress and development. 

A recent report from Beauhurst, titled Spotlight on Start-ups, found that Britain has experienced the biggest growth in life science patent applications across all big European markets in the past decade, while British academic spinouts secured £2.13bn of equity investment despite a global slowdown in fundraising levels across the science and technology sectors.

Investors are also buoyed by the government’s decision to double down on the ‘science superpower’ ambition by introducing policies that will allow start-ups and scale-ups to attract more institutional investment. Seventy venture capital and growth investors with a collective £100bn in assets under management have now signed up to the Venture Capital Investment Compact. The body’s primary purpose is to get more pension money flowing into start-ups.

Read more

Amentum Selected for Projects to Upgrade and Protect the UK Energy Grid

It’s crucial to highlight that irrespective of market fluctuations (even though investor sentiment is currently upbeat), the progression of science is independent of economic cycles and continues its steady advance. The enduring need for long-term patient care and novel therapies persists; considering the vast spectrum of over 10,000 known diseases, cures have been found for only five per cent of them.

With the public and private sectors throwing their weight behind UK life sciences and global demographic trends driving a need for life-saving treatments, there is an urgent need to speed up the delivery of mission critical purpose-built facilities. 

Because science happens in proximity, and not in isolation, space must be delivered in the right locations.

In Cambridge, a city that is home to a world-leading university and top UK life science companies, vacancy rates for lab and office space are under one per cent. Companies are vying for limited space, in turn locking out the types of start-ups and scale-ups that will spearhead the UK’s ambition to transform into a US-style supercluster.

Ground-breaking research and discovery cannot be undertaken from a kitchen table, meaning that unlike sectors like professional and financial services, UK life sciences’ growth depends on the delivery of more purpose built, suitable space. 

There now exists a cross-party consensus that the UK’s Fourth Industrial Revolution will be powered by a digitally enabled economy that promotes the convergence of technology and science.

Such market fundamentals are the driving factors behind our decision to increase our strong presence in the UK. This expansion potential is designed to ensure that promising start-ups and scale-ups have access to critical lab spaces, preventing them from being locked out of the market. After all, it is physical infrastructure that will enable Britain to continue its positive trajectory in research and scientific discovery.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Opinion

Categories

  • Opinion

Trending Articles

  • Victoria Beckham owed £350,000 by Harvey Nichols

  • M&G: FTSE 100 giant hits out at Rayner’s ground rent cap as it suffers loss

  • Fulham owner Khan sees his £1bn stadium construction project take next steps

  • John Lewis boss: UK economy facing a ‘permacrisis’ 

  • Don’t underestimate the free trade agreement Britain just joined

More from Morning Wire

  • Amentum Selected for Projects to Upgrade and Protect the UK Energy Grid

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Osmose Europe Ltd. Strengthens and Expands Electric Utility Infrastructure Solutions with the Acquisition of MP Power Ltd.

    Business Wire
  • Credo Technology: The next big opportunity in AI?

    Opinion
    Close-up of fiber optic cables and connectors in a server rack, illustrating data center technology and connectivity.
  • Healey facing £6bn hit as UK borrowing costs reach highest point since financial crisis 

    Markets
    A smiling man in a dark suit and red tie looking slightly upwards, against a plain background.
  • As it happened: Vodafone leads FTSE 100 rally after TV launch; oil jumps again

    FTSE 100 Live
    Vodafone and Three company logos on a red and white sign outside a modern glass building
  • Heathrow overtaken by Istanbul as Europe’s busiest airport

    Transport & Infrastructure
    Commercial airplane landing at Heathrow Airport, seen from behind, with a prominent Heathrow sign below.
  • Balfour Beatty ups profit forecasts as it defies construction gloom

    Transport & Infrastructure
    Balfour Beatty construction site showcasing cranes, workers, and building progress against a city skyline backdrop
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook